Publication | Closed Access

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologySolid TumoursPathologyImmune Checkpoint InhibitorEzh2 InhibitorOncologyRadiation OncologyCancer Research